Metformin, a drug approved by the U.S. Food and Drug Administration (FDA) for use in patients with diabetes, has been shown to improve fatty livers in animals and in a small number of human beings.
The purpose of this study is to find out if Metformin is safe and useful in the treatment of non-alcoholic fatty liver disease (NAFLD).
To participate in this study, you must:
Your participation in this study will last about two years. You will be randomly assigned to receive either Metformin or a placebo for one year. After your year of dosing, there will be a follow-up period that lasts for another year.
For more information, contact Christopher Kigongo at 919-668-6579.